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Abstract: DNA replication is a highly demanding process regarding the energy and material supply
and must be precisely regulated, involving multiple cellular feedbacks. The slowing down or stalling
of DNA synthesis and/or replication forks is referred to as replication stress (RS). Owing to the
complexity and requirements of replication, a plethora of factors may interfere and challenge the
genome stability, cell survival or affect the whole organism. This review outlines chemical compounds
that are known inducers of RS and commonly used in laboratory research. These compounds act
on replication by direct interaction with DNA causing DNA crosslinks and bulky lesions (cisplatin),
chemical interference with the metabolism of deoxyribonucleotide triphosphates (hydroxyurea),
direct inhibition of the activity of replicative DNA polymerases (aphidicolin) and interference with
enzymes dealing with topological DNA stress (camptothecin, etoposide). As a variety of mechanisms
can induce RS, the responses of mammalian cells also vary. Here, we review the activity and
mechanism of action of these compounds based on recent knowledge, accompanied by examples of
induced phenotypes, cellular readouts and commonly used doses.
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1. Introduction
The DNA molecule always has to keep the middle ground: it must be sufficiently rigid to maintain
correct genetic information while at the same time available for ongoing processes. DNA is particularly
vulnerable to insults during replication, a process where a copy of the genome is generated [1].
Replication must be tightly regulated because it is essential for genome integrity, and therefore the
fate of a new cellular generation. Accurate coordination of several cellular pathways is needed to
provide sufficient energy and material supply, precise timing and functional repair to overcome arising
difficulties [1].
Transient slowing or disruption of replication fork (RF) progression is called replication stress
(RS), which can be caused by a limitation of important factors and/or obstacles caused by intrinsic
and extrinsic sources [2]. Intrinsic sources of RS involve the physiological properties of the DNA
molecule, such as regions of heterochromatin structure, origin-poor regions or sites rich in some types
of repetitive sequences [3–5]. Other intrinsic sources of RS are generated by deregulated pathways
that cause over- and under-replication [6–8], re-replication (also known as re-duplication) [9,10], or by
transcription and replication machinery collisions [9].
The most common extrinsic sources of RS are all wavelengths of ultraviolet radiation (UV) [11],
ionising radiation (IR) [12] and special genotoxic chemical compounds [13] which are the main focus
of this review. RS-inducing chemicals can cause a broad spectrum of DNA lesions. Alkylating
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agents such as methyl-methane sulfonate (MMS) [14], temozolomide and dacarbazine [15] directly
modify DNA by attaching an alkyl group that presents an obstacle to RF progression. Moreover,
the bifunctional alkylating compounds (e.g., mustard gas) can cause the crosslinking of guanine
nucleobases [16,17] that violate the DNA structure even further [18]. Typical crosslinking agents
introduce covalent bonds between nucleotides located on the same strand (intrastrand crosslinks),
like cisplatin, or opposite strands (interstrand crosslink), like mitomycin C, and psoralens [18].
Crosslinks make the strands unable to uncoil and/or separate and physically block RF progression [19].
Even a small amount of unrepaired crosslinks (approx. 100–500) is reported to be lethal to a mammalian
cell [20]. Furthermore, single-strand DNA breaks (SSB) and double-strand DNA breaks (DSB) represent
a specific problem for ongoing replication which is well manifested by increased sensitivity of
replicating cells towards radiomimetic compounds (e.g., neocarzinostatin) [21]. Other compounds
do not damage the DNA structure directly but rather interfere with replication-related enzymes.
Aphidicolin, an inhibitor of replicative DNA polymerases leads to uncoupling of the replicon and
generation of long stretches of single-stranded DNA (ssDNA) [22]. After hydroxyurea treatment,
an inhibitor of ribonucleotide reductase (RNR), the metabolism of deoxyribonucleotide triphosphates
(dNTPs) is disturbed, and subsequently, the RF progression is blocked [23]. Camptothecin and
etoposide, inhibitors of topoisomerase I and topoisomerase II respectively, prevent DNA unwinding
and halt relaxation of torsional stress [24,25]. The most common sources of RS are illustrated in
Figure 1.
Several repair pathways are essential for rapid elimination of DNA distortions and lesions
introduced by the action of RS inducing compounds [26]. Removal and replacement of single
base damage (e.g., oxidised and alkylated bases), is performed by base excision repair (BER) [27].
More extensive damage affecting several adjacent bases is repaired by nucleotide excision repair
pathway (NER). NER is essential for repair of UV-induced damage such as cyclobutane pyrimidine
dimers, or pyrimidine-pyrimidone (6-4) photoproducts and also needed for crosslinks removal caused
by for example cisplatin [28]. Single-strand break repair in higher eukaryotes rely on poly(ADP-Ribose)
polymerase 1 (PARP1) and X-ray repair cross complementing 1 (XRCC1) depedent recognition of
the lesion, followed by end processing and ligation [29]. Double-strand breaks (DSBs) are processed
by either homologous recombination (HR), or non-homologous end-joining (NHEJ). HR is active
predominantly in S and G2 phases using the sister chromatid as a template for repair with high
fidelity [30]. NHEJ, considered as an error prone pathway, performs DSB repair in all cell cycle stages
more rapidly by direct ligation of two unprocessed (or minimally processed) DNA ends [31].
All previously described specific structures and concomitant DNA lesions can challenge the
progression of RF. If the RF encounters a lesion which the replicative polymerase is unable to process as
a template, it becomes stalled [32]. Stalled RFs are vulnerable structures and may undergo spontaneous
collapse which leads to DSBs and genomic instability (GI) [33,34]. To avoid the harmful consequences
of stalled forks, several mechanisms—DNA damage tolerance pathways (DDT)—exist to bypass the
lesions and enable fork restart. One well-described process of DDT is translesion synthesis (TLS).
TLS promotes “polymerase switch” from the replicative polymerase to translesion polymerases,
which are able to continue replication across the lesion. TLS polymerases possess low processivity
and fidelity towards the template DNA strand. Therefore TLS is often referred to as the error-prone
pathway of DDT [32,34–36]. Among the DNA lesions which block the progression of RFs, interstrand
crosslinks (ICLs) belong to the most challenging to bypass [37]. Thus, a whole group of proteins called
Fanconi anaemia (FA) proteins evolved to govern the bypass and the repair of ICLs. The FA network
promotes the unhooking of the ICL by specific endonucleases, bypassing the lesion by TLS polymerases
or the repair by HR [5–7]. Patients with a defect in the FA protein family suffer from premature ageing,
show increased sensitivity to DNA crosslinking agents (e.g., cisplatin, mitomycin C) and predisposition
to certain types of cancers due to increased GI [38–40]. Although the FA pathway is involved mainly
in ICL repair, it contributes more generally to initial detection of RF arrest, processing and stabilisation
of the forks and regulation of TLS [41,42].
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DNA damage bypass can occur in an error-free manner through the activation of the other
branch of DDT, called template switching (TS). The process utilises the newly synthesised strand
of the sister duplex, using it as an undamaged template. TS can be promoted either by fork
regression or by strand invasion mediated by HR [34,36,43,44]. RF restart can also be achieved
by firing nearby dormant replication origins or by repriming events leaving behind lesion containing
single-stranded DNA (ssDNA) gaps which are subsequentially processed by DTT pathways [45–50].
Altogether, these processes ensure the rapid resumption of DNA synthesis, preventing prolonged fork
stalling and the potentially deleterious effects of replication fork collapse. However, upon persisting
RS, or non-functional RS response, the RF may fail to restart and collapse, most probably
due to destabilised, dysfunctional or displaced components of replication machinery [1,50–54].
Prolonged stalled replication forks are targeted by endonucleases followed by recombination-based
restart pathways [55,56].
Among the features of RS belong accumulation of long stretches of ssDNA [46,57], resulting from
the uncoupled activity of DNA polymerase and progression of DNA helicase [58,59]. The persisting
ssDNA is rapidly coated by replication protein A (RPA) that in turn generates the signal triggering
the checkpoint response through activation of Ataxia telangiectasia Rad3-related (ATR) checkpoint
kinase [60–63]. Once activated, ATR and its downstream target checkpoint kinase 1 (CHK1) help the
cell to faithfully complete DNA replication upon RS [52,53,64]. In addition, ATR as the central RS
response kinase contributes to the stabilisation and restart of the stalled forks even after the stress has
been removed [65]. The ATR-CHK1 pathway is responsible for cell cycle inhibition, suppression of new
origin firing, DNA repair and to the overall improvement of cell survival [62,66]. The role of Ataxia
telangiectasia mutated (ATM), another important checkpoint kinase, upon RS conditions is not as clear
and straightforward as of ATR. ATM is preferentially activated by DSBs which are generated in later
stages after RS induction, mostly after the RF collapse [67,68]. There is suggested interplay between
ATM and ATR during replication stress which becomes apparent under concomitant depletion of
both kinases [68]. Interplay between ATM, Werner helicase (WRN) and Bloom helicase (BLM) is
needed for the resolution of replication intermediates and HR repair pathway that is important for RF
restart [69,70].
Chronic replication stress conditions, particularly in the absence of proper DNA repair pathway
and/or non-functional checkpoint responses might result in the transfer of RS-related DNA alterations
to daughter cells, inducing mutations, GI and fuelling tumourigenesis [1].
From this point of view, the RS is a strong pro-carcinogenic factor driving selective pressure for
acquisition of mutations overcoming cell cycle arrest or apoptosis [71,72]. This further leads to the
progression of malignant transformation and faster selection of mutations allowing development of
resistance to cancer treatment [73].
However, cells typically react on the prolonged exposure to RS by triggering mechanisms leading
to permanent cell cycle arrest known as cellular senescence or apoptosis [74,75] acting as a natural
barrier against tumour progression [76].
Several hereditary syndromes are linked to enhanced RS and GI. The spectrum of exhibited
symptoms is broad and includes premature ageing, growth retardation, neurodegeneration,
immunodeficiency, cancer predisposition and others. The disorders like Seckel syndrome (deficiency in
ATR kinase) [77], Ataxia telangiectasia caused (loss of ATM kinase) [78], Xeroderma pigmentosum
(XP); various defects in XP protein family group) [79] are caused by aberrations in DNA damage
recognition and repair enzymes [80]. Bloom and Werner syndrome (deficiency of BLM and WRN
helicase, respectively) [81,82], Fanconi anaemia (FA; mutations in FA pathway proteins) [83,84],
or Rothmund-Thomson syndrome (defects in RECQ like helicase 1 protein) [85,86] are related to
failure of replication fork progression and restart.
In general, RS is a potent inducer of variety of hereditary and non-hereditary diseases,
including the oncogenic transformation. The knowledge and understanding of the processes during
RS are crucial for choosing the most efficient therapy. The in vitro-based cell studies involving models
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of chemical induction of RS are unique source of information about molecular interactions and
undergoing mechanisms. For this review five compounds were chosen, all of them are commonly used
for cell-based experiments to induce RS. Several aspects are discussed in detail: mechanism of action
aimed at replication interference, proper dosing and common experimental setups. A brief overview
of the medical use and important practical hints for laboratory use are also included.
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Figure 1. Schematic view of the most common lesions causing replication stress. In the scheme,
several important replication stress (RS) inducing factors are illustrated: intra-strand crosslink (ISC),
inter-strand crosslink (ICL), alkylated/modified base (Me) and inhibition of replication related
enzymes. Compounds further described in the review are arked by red c l ur. RNR: ribonucleotide
reductase; DNA pol.: DNA polymerase; TopoI: topoisomerase I; TopoII: topois m rase II;
APH: aphidicolin; HU: hydroxyurea; CPT: camptothecin; ETP: etoposide; cisPt: cisplatin;
dATP: deoxyadenosine triphosphate; dTTP: deoxythymidine triphosphate; dCTP: deoxycytidine
triphospahte; dGTP: deoxyguanine triphosphate.
2. Compounds
2.1. Cisplatin
Cisplatin (cisPt) is an inorganic platinum complex first synthesised by Italian chemist Michel
Peyrone and originally known as ‘Peyrone’s chloride’ (Figure 2). The cytostatic activity of cisPt was first
reported by Barnett Rosenberg and co-workers in 1965 following accidental discovery of Escherichia coli
growth inhibition induced by the production of cisPt from platinum electrodes [87]. It is generally
considered as a cytotoxic drug for eating cancer cells by damaging DN and inhibiting DNA
synthesis. cisPt is a neutral planar coordination complex of divalent platinum [88] with two labile chloride
groups and two relatively inert amine ligands. The cis configuration is necessary for the antitumour
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Figure 2. Cisplatin structu e.
2.1.1. Mechanism of DNA Damage Induction
The cytotoxicity of cisPt is known to be due to the formation of DNA adducts, including
intrastrand (96%) and interstrand (1%) DN cr sslinks, DNA monoadduct (2%) nd DNA–protein
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crosslinks (<1%) [91]. These structural DNA modifications block uncoiling and separation of DNA
double-helix strands, events both necessary for DNA replication and transcription [92]. Inside a cell, cisPt
forms an activated platinum complex, which triggers a nucleophilic substitution reaction via an attack on
nucleophilic centres on purine bases of DNA, in particular, N7 positions of guanosine (65%) and adenosine
residues (25%) [93]. The two reactive sites of cisPt enable the formation of the most critical crosslink
between two adjacent guanines (1,2-d(GpG)), resulting in the formation of DNA intrastrand crosslinks [94].
Also, platinum can align to guanine bases on the opposite DNA strand, thus creating DNA interstrand
crosslinks, present in lower percentage [95]. These cisPt crosslinks create severe local DNA lesions that
are sensed by cellular proteins, inducing repair, replication bypass or triggering apoptosis [96]. Several
protein families can recognise cisPt–DNA adducts, including nucleotide excision repair (NER) proteins [97],
homology-directed repair proteins (HDR) [98], mismatch repair (MMR) proteins [99] and non-histone
chromosomal high mobility group proteins 1 and 2 (HMG1 and HMG2) [100]. The intrastrand cisPt
structural alteration stalls RNA polymerase II. It is recognised and efficiently repaired by global genome
NER (GG-NER) or its transcription-coupled sub-pathway (TC-NER) [101]. The second DNA repair system
predominantly involved in coping with cisPt–DNA adducts is error-free HDR, which removes DNA DSBs
remaining after cisPt adduct removal [98]. In contrast to the previously mentioned repair pathways that
increase cell viability, MMR proteins have been shown to be essential for cisPt-mediated cytotoxicity [99].
cisPt is reported to enhance interactions between MMR proteins MLH1/PMS2 (MutL homolog 1/PMS1
homolog 2, MMR component) and p73, triggering apoptosis [102]. Therefore, mutations in MMR genes
are known to be associated with cisPt resistance [103]. HMG1 and HMG2 recognise intrastrand DNA
adducts between adjacent guanines, affecting cell cycle events and subsequently inducing apoptosis [100].
In addition to the previously mentioned repair proteins, specialised translesion DNA polymerase
eta (η) can be loaded onto sites of cisPt–DNA adducts promoting TLS repair pathway [104]. cisPt
also induces dose-dependent reactive oxygen species (ROS), which are responsible for the severe
side effects of platinum-based therapy, including nephrotoxicity and hepatotoxicity [105]. When
overwhelming the reduction capacity of the cell, cisPt-induced ROS might lead to lipid peroxidation,
oxidative DNA damage, altered signal transduction pathway and calcium homoeostasis failure [105].
Extensive unrepaired cisPt-induced DNA damage can proceed to apoptotic cell death mediated by
various signal transduction pathways, including calcium signalling [106], death receptor signalling [107]
and activation of mitochondrial pathways [108]. At least two main pathways have been proposed to
mediate cisPt-induced apoptosis in vitro. One involves the critical tumour suppressor protein p53 directly
binding to cisPt-modified DNA [109] and promoting apoptosis via several mechanisms. p53 binds and
counteracts the anti-apoptotic B-cell lymphoma-extra large (Bcl-xL) [110], contributes to inactivation of
nutrient sensor AMP-kinase (AMPK) [111], activates caspase-6 and -7 [112] and the pro-apoptotic
Bcl-2 family member PUMAα in renal tubular cells [113]. However, the role of p53 in response to cisPt
seems to be controversial, as it has been described to contribute to cisPt cytotoxicity [114] and also
to be involved in cisPt resistance in different cancer models [115]. The other cisPt-induced apoptotic
pathway is mediated via a pro-apoptotic member of the p53 family, p73. cisPt has been shown to
induce p73 in several cancer cell lines [116], which cooperates with the MMR system and c-Abl
tyrosine kinase, known to be involved in DNA damage-induced apoptosis [117]. In response to cisPt,
c-Abl phosphorylates p73, making it stable [118], and increases its pro-apoptotic function by binding
transcription coactivator p300, which triggers transcription of pro-apoptotic genes [119]. Moreover,
p73 forms a complex with c-Jun N-terminal kinase/stress-activated protein kinase (JNK), leading to
cisPt-induced apoptosis [120]. Intrinsic signaling pathways involved in cisPt driven apoptosis include
Akt [121], protein kinase C [122,123], and mitogen activated protein kinases—MAPK (e.g., extracellular
signal-regulated kinases; ERK) [124–126], JNK [127–129] and p38 [130].
2.1.2. Other Effects
Besides DNA, the primary target of cisPt in cells, there is some evidence for the involvement of
non-DNA targets in cisPt cytotoxicity [131]. cisPt interacts with phospholipids and phosphatidylserine
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in membranes [132], disrupts the cytoskeleton and alters the polymerization of actin, probably due to
conformational changes resulting from the formation of Pt–S bonds [133]. MicroRNAs (miR), which play
a role in posttranscriptional gene silencing, have been shown to be involved in the modulation of cisPt
resistance-related pathways in different cancer models. miR-378 was shown to reverse resistance to cisPt in
lung adenocarcinoma cells [134], whereas miR-27a was shown to be upregulated in a multidrug resistant
ovarian cancer cell line, contributing to cisPt resistance [135]. miR-21 increases the cisPt sensitivity of
osteosarcoma-derived cells [136]. For references to particular studies using cisPt, refer to Table 1.
Table 1. Effects of various cisplatin treatments in vitro.
Concentration Incubation Time Observed Effect Cell Line Reference
300 µM 2 h increase in polyADP ribosylation
O-342 rat ovarian
tumour cells [137]
100 µM 2 h before IR sensitization to γ-radiation hypoxic V-79Chinese hamster cells [138]
100 µM 2 h increase in polyADP ribosylation CV-l monkey cells [139]
<20 µg/mL
(<66 µM) 5 h
block of rRNA synthesis
block of DNA replication Hela [140]
15 µM 1 h induction of SCE (sister chromatid exchange)decreased cell survival
6 primary human
tumour cell culture [141]
10–30 µM 24 h, 48 h induction of apoptosis 224 (melanoma cells)HCT116 [142]






2–10 µM 72 h induction of apoptosis 224 (melanoma cells)HCT116 [142]
5 µM 24 h
increase in p53 stability
activation of ATR increased p53(ser15)
phosphorylation
A2780 [144]
5 µM 24 h
activation of p21
activation of CHK2 increased p53(ser20)
phosphorylation
HCT116 [144]





2 µM 24 h G2/M arrest, subapoptic damage MSC [145]
>2 µM 24 h decreased proliferation rateinduction of apoptosis
TGCT H12.1
TGCT 2102EP [145]
1–4 µg/mL 2 h
block of DNA synthesis
L1210/0 cells [146]block of transcriptionG2 arrest
apoptosis
2 µg/mL 48 h144 h, 168 h
inhibition of mtDNA replication





1 µg/mL 2 h transient G2 arrest Hela [148]
3.0 µM 4 h before block of NHEJ A2780 [138]
0.2–0.8 µM IR 0.5 Gy cisPt-IR synergistic interaction MO59J
MO59K
[138]4 h
1–2.5 µM 24 h–48 h block of DNA replication followed by cellapoptosis Hela [149]
0.3–1 µM overnight inhibition of RNA polymerase II-dependenttranscription
Hela
XPF [144]
0.6 µM 2 h
90% reduction in clonogenic capacity detected
after 7 days
CHK1 phosphorylation causing CHK1
dependent S phase arrest
Hela [148]
0.5 µM 24 h
48 h
loss of telomeres (TEL), or TEL repeats
cell death Hela [139]
ATR: Ataxia telangiectasia Rad3-related; Bcl: B-cell lymphoma; CHK1: checkpoint kinase 1; CHK2: checkpoint
kinase 2; IR: ionizing radiation; mtDNA: mitochondrial DNA; NHEJ: non-homologous end-joining; PKC: protein
kinase C; polyADP: poly adenosine diphosphate; rRNA: ribosomal RNA.
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2.1.3. Solubility
cisPt (molecular weight (MW) 300.05 g/mol) is water soluble at 2530 mg/L (at 25 ◦C),
saline solution with a high chloride concentration (approx. 154 mmol/L) is recommended. In the
absence of chloride, the cisPt chloride leaving group becomes aquated, replacing the chloride
ligand with water and generating a mixture of species with increased reactivity and altered
cytotoxicity [150,151]. Commonly used solutions for laboratory use are aqueous-based solutions
in 0.9% NaCl (0.5 mg/mL), pH 3.5–5. Dissolved cisPt may degrade over a short time, the storage of
aliquots is not recommended. However, the stability at −20 ◦C in the dark is reported to be 14 days.
Solutions (in 2 mM phosphate buffered saline buffer with chloride concentration 140 mmol/L) stored
at 4 ◦C should be stable for 7–14 days [152]. Undiluted cisPt is stable in the dark at 2–8 ◦C for several
months [121,153]. Dimethyl sulfoxide (DMSO) can also be used for cisPt dilution, however it is
not recommended. The nucleophilic sulphur can displace cisPt ligands, affecting the stability and
reducing cisPt cytotoxicity [154]. DMSO introduced in combination studies with cisPt does not affect
its activity [152].
2.1.4. Medical Use
Following the start of clinical trials in 1971, cisPt, marketed as Platinol (Bristol-Myers Squibb,
New York, USA), was approved for use in ovarian and testicular cancer by the Food and Drug
Administration (FDA) in 1979 [155]. cisPt is considered one of the most commonly used chemotherapy
drugs for treating a wide range of malignancies, including head and neck, bladder, oesophagal,
gastric and small cell lung cancer [156,157]. Moreover, cisPt has been shown to treat Hodgkin’s [158]
and non-Hodgkin’s lymphomas [159], neuroblastoma [160], sarcomas [161], multiple myelomas [162],
melanoma [163], and mesothelioma [164]. cisPt can reach concentrations of up to 10 µg/mL in human
plasma [165]. cisPt is administrated either as a single agent or, in the main cases, in combination with
other cytostatics (e.g., bleomycin, vinblastine, cyclophosphamide) or radiotherapy for the treatment
of a variety of tumours, e.g., cervical carcinoma [153]. The most important reported side effect
is nephrotoxicity, due to preferential accumulation and persistence of cisPt in the kidney [166],
later ototoxicity and bone marrow depression. Pharmacokinetic and pharmacodynamic studies
have shown that a maximal steady state cisPt plasma concentration of between 1.5 and 2 µg/mL has
the most effective chemotherapeutical effect with minimal adverse nephrotoxicity [167]. Many cancers
initially responding to cisPt treatment could become later resistant. Mechanisms involved in the
development of cisPt resistance include changes in cellular uptake, drug efflux, drug inactivation
by increased levels of cellular thiols, processing of cisPt-induced damage by increased NER and
decreased MMR activity and inhibition of apoptosis [99,168]. To boost platinum drug cytotoxicity,
overcome its resistance and achieve a synergistic effect, new platinum-based drugs, as well as their
combinatorial therapy with other antineoplastic agents were developed for cancer treatment [169].
Besides of cisPt derivatives as carboplatin and oxaliplatin, are currently being used in the clinical
practice, while nedaplatin, lobaplatin and nedaplatin acquired limited approval in clinical use [170,171].
Recent discoveries described the combination of cisPt with PARP inhibitor olaparib targeting DNA
repair to acts synergistically in several non-small cell lung carcinoma cell lines [172]. This combinatorial
therapy can be promising especially in patients with advanced breast and ovarian cancer-bearing
BRCA1/2 (breast cancer 1/2) mutations [173].
2.1.5. Summary
cisPt is used in vitro in concentration range approx. 0.5–300 µM. The levels in human plasma
can reach up to 10 µg/mL (33 µM) which should be beared in mind when interpreting in vitro data.
Continuous treatment, or longer incubation time, or high cisPt concentration of 20 mg/mL lead
to complete inhibition of DNA synthesis [174]. The concentration range of 15–30 µM results in a
block of DNA replication and transcription and triggers DNA damage response (DDR) signalization
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through ATM-CHK2, ATR-CHK1 DDR pathways resulting in p53-p21 driven cell cycle arrest or
p53-mediated cell apoptosis [141–144]. However, in some cell lines also the synthesis of anti-apoptotic
protein Bcl-2 was reported [143]. cisPt is in the majority of cell lines induces apoptosis above the
concentration of approx. 2 µM [139,141,142,146]. cisPt block DNA replication [139,140,146] and
inhibits RNA synthesis [140,175,176] and also influences the mitochondrial DNA synthesis and
metabolism [147]. As a commonly used drug in clinics, many in vitro experiments have been conducted
to address problems arising during treatment. Especially, the study of mechanisms underlying drug
resistance [177], causes of toxic side effects [178], enhancement of synergistic effects [179] and ways how
to improve drug delivery systems [180]. cisPt massively triggers the TLS repair pathways; defective FA
proteins sensitise the cells towards this compound [181], defective MMR proteins establish cisPt
resistance [103,182].
2.2. Aphidicolin
Aphidicolin (APH) is a tetracyclin diterpenoid antibiotic isolated from Nigrospora sphaerica
(Figure 3) which interferes with DNA replication by inhibiting DNA polymerases α, ε and δ [183].
Specifically, only cells in S phase are affected, whereas cells in other phases of the cell cycle are left to
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even at conce trations completely blocking the polymerase activity [183]. However, in the cell n cleus,
the exonucl ase activity is sually not retained because ternary is
for ed and blocks the enzy e [183]; 3D structure of the complex can be found here [187].
ec i ti ll , P co pro ises the function of D poly erase, hile helicase proceeds
regularly (so cal ed uncoupled/ t licon), hich lea s t t r tion f l t tc es
of single-stra e [188]. isc t r li is l r l str ct re ro e for breakage
preferentiall at the so-call c f i
FSs are specific ge ic l ci c s r i
FS expressi is also co on in precancerous and cancerous lesions [76]. re r, a causative
role f ’ l t as been suggested [191]. APH reproducibly cau es damage
at the same sites, and thus low d ses of APH are used to define APH-inducible CFSs, of which
there are over 80 described in th human genome [22,192]. Oth r CFS inducers (hydroxyurea,
camptothecin, hypoxia and folat deficiency) are not so specific, nor efficient as APH [193,194].
Importantly, APH efficiently induces CFS expression only when the rat of polymerase is slowed down
but not completely block d. The optimum concentration range usually spans 0.1–1 µM [195] (and refer
to Table 2). Apart from disco nected replicon, there might be other l i i r
potency of P to i ce S-associated geno ic i stability. First, P has been s o n t i crease
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the number of R-loops within certain CFSs, thus inducing replication/transcription collisions [196].
However, the mechanistic relationship between APH and increased R-loop formation is not clear.
Second, re-licensing of replication origins is typical feature of oncogenic genetic backgrounds which
are very prone to CFS expression. In such situations the CFS expression is explained as a result of DNA
re-replication and subsequent collision of re-replicating forks within CFSs [10,197]. This phenomenon
was studied in detail in yeasts at replication slow zones (analogs to CFSs in mammals) [198]. It is not
clear whether the same re-licensing process is induced also by APH, however re-duplication would
explain the reported APH-induced amplifications [191,199].
Prolonged treatment with low doses of APH induces cellular senescence response [74].
Interestingly, the most efficient doses were found to span the same range as doses used
for CFS expression, which implies that CFSs might play a causative role in this process.
Moreover, oncogene-induced senescence also displays increased CFSs-associated instability [10,197].
These phenotypical similarities between oncogenic stress and low doses of APH make this drug a
good candidate for studying cellular processes in early stages of malignant transformation.
2.2.2. Other Effects
APH is a very specific DNA polymerase inhibitor, APH does not interact with mitochondrial DNA
polymerases [186] nor proteins [200], DNA, RNA, metabolic intermediates, nor nucleic acid precursor
synthesis [184,200,201]. Contradictory results have been obtained regarding the effect of APH on
DNA repair synthesis (DRS). According to a radiography method, APH does not influence DRS [200],
although when DRS was induced by tumor necrosis factor (TNF) or UV irradiation, APH was observed
to inhibit the process [202,203]. For references to particular studies using APH, refer to Table 2.
Table 2. Effects of various aphidicolin treatments in vitro.
Concentration Incubation Time Observed Effect Cell Line Reference
0.2 mM 16 h, 10 h formation of anaphase bridges and micronuclei HeLa [204]
30 µM 6 h stalled replication forks HCT116 [205]
30 µM 6 h stalled replication forks PD20 cellsBloom syndrome cells [206]
5 µg/mL
(14.3 µM) 4 h
DNA repair synthesis inhibition






(14.3 µM) 2–8 h
S phase arrest











10 µM 15 h cell cycle synchronisation at the G1/Sboundary
REF-52
HeLa [208]
5–25 µM 24 h inhibition of replicative polymerases Werner syndrome cellsBloom syndrome cells [209,210]
1 µM 1–24 h CFS induction HEK293T [210]
1 µM 24 h CFS induction
MEF
HeLa [211]
0.5 µM 2 h transient attenuation of DNA synthesis, DT40 [212]
0.1 µM 24 h study of chromosome integrity and replication
0.4 µM 24 h CFS induction U-2 OS [213]
0.1 µM
0.2 µM 16 h replication stress observed on telomeres hESC (UCSF4) [214]
0.2 µM 2 weeks irreversible senescence induction REF-52 [74]
0.2 µM 24 h CFS induction BJ-hTERT [215]
0.05 µM
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Table 2. Cont.
Concentration Incubation Time Observed Effect Cell Line Reference
0.3 µM 48 h
increased incidence of mitotic extra
chromosomes
replication stress
V79 hamster cell lines [217]
0.3 µM 72 h replication stress Human fibroblastsHGMDFN090 [199]





0.2 µM 7–24 h cell synchronization HeLa [184]
CFS: common fragile site; TNF: tumour necrosis factor.
2.2.3. Solubility
APH (MW 338.48 g/mol) is soluble in DMSO (up to 10 mg/mL), ethanol (up to 1 mg/mL) and
methanol (freely), not soluble in water. The stability of the powder is 3 years at 2–8 ◦C, ethanol solution
for a week at 2–8 ◦C, DMSO solution for 6 weeks at −20 ◦C [218].
2.2.4. Medical Use
APH has limited use in clinical practice owing to its low solubility. Only APH-glycinate has so far
been tested in clinical trial phase I. However, fast clearance from human plasma (no drug observed
after 6–8 h of APH administration) and no anti-tumour activity was observed. Its use as a single agent
or even in combination with other cytostatics is no longer being considered [219]. APH is metabolised
by cytochrome P-450 dependent degradation [220]. APH and its derivatives are considered as potential
therapeutics for parasitic diseases, e.g., Chagas disease [221].
2.2.5. Summary
APH is used for in vitro studies in concentration range approx. 0.01 µM to 0.2 mM. APH is mainly
used for cell-based experiments involving CFS expression [222], cell cycle synchronization [223],
replication fork stability and restart studies [224] and for cellular senescence induction [74].
The threshold between replication fork stalling and slowing down is around 1 µM. Upon higher
concentrations (5 µM–0.2 mM) APH was reported to stall the DNA polymerase, leading to S phase
arrest. Upon lower concentrations, when the DNA polymerases are just slowed down, CFS expression
can be observed. Usually, longer incubation times (approx. one population doubling) are used, so more
cells within the population are affected. APH treatment causes a significant amount of DNA damage,
leading to rapid ATR kinase activation. In the case of longer APH treatment also ATM is activated probably
as a consequence of DSB formed within the stalled replication forks [207]. Prolonged APH incubation in
the range of days up to weeks at low concentrations (0.2–1 µM) induces cellular senescence [74].
2.3. Hydroxyurea
Hydroxyurea (HU) was first synthesised in the 19th century (Figure 4) and inhibits the
incorporation of nucleotides by interfering with the enzyme ribonucleotide reductase (RNR) [225].
RNR converts nucleotide di- and tri-phosphates to deoxynucleotide di- and tri-phosphates, which is
the rate-limiting step in nucleotide synthesis [226]. Without proper levels of dNTPs, DNA cannot be
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2.3.1. Mechanism of DNA Damage Induction
RNR is a large tetrameric enzyme comprising two R1 subunits and two small regulatory subunits
R2 [228]. HU scavenges the tyrosyl radical of the R2 subunit which inactivates the RNR enzymatic
activity [226]. Complete inhibition of RNR has been observed within 10 min after treatment with
0.1 mM HU and within 5 min after 3 mM of HU in murine 3T6 cells [229]. Consequently DNA synthesis
is inhibited, selectively stopping the cells in S phase [230]. The inhibition is caused alterations in
the dNTP pools. Each type of dNTP is affected in a different way. For example, after 280–560 µM
HU treatment for 60 min, the dTTP pool was found to increase by 50%, whereas the dCTP pool is
decreased by 50% [231]. HU slows down the initiation of replication and also the progression of
replication forks. Moreover, after stopping the production of dNTPs, DNA repair and mitochondrial
DNA synthesis are affected in all cells, regardless of the cell cycle stage [227]. HU treatment greatly
affects the choice of replication origins and origin spacing in mammalian cells [232]. Although the
mechanism of DNA damage induction may look similar to that for APH, HU induces a different
spectrum of fragile sites, called early replicating fragile sites (ERFs) [233]. ERFs are also induced by
c-Myc expression [11,12]. It was also reported that 10 µg/mL APH [234] (concentration that stalls
the replication fork progression) leads to the generation of several kilobases long unwound DNA;
however, HU treatment can generate only up to 100–200 nt long ssDNA [235].
2.3.2. Other Effects
HU induces copy number variants (CNVs) with similar frequency and size distribution as
APH [236]. It was reported for yeast cells, that HU alters Fe–S centres, enzyme cofactors catalysing
oxidation-reduction reactions, which interferes with various metabolic enzymes and affects the redox
balance of cells. Similar mechanism is proposed also for mammalian cells [237].
HU has been negatively tested for mutagenicity, measured by single nucleotide variation (SNV)
and insertion/deletion frequency [238]. On the other hand, low doses of HU have been reported to
induce DNA damage [239]. Therefore, it is possible that the compound possesses some pro-mutagenic
potential (see also below). For references to particular studies using HU, refer to Table 3.
Table 3. Effects of various hydroxyurea treatments in vitro.
Concentration Incubation Time Effect Cell Line Reference
200 mM 2 h replication block yeast cells [240]
10–200 mM 3 h replication blockreplication fork (RF) restart yeast cells [241]
5 mM 1 h replication block
HEK293 [242]
2 mM 3 h replication block
50 µM–5 mM 40 min–2 h replication stress
293T
mouse ES cells [243]
2 mM 1 h, 24 h replication stressreplication block
HCC1937
MCF7 [244]
2 mM 16 h replication block HEK293 [245]
2 mM 24 h DNA damage induction during S phase
U-2 OS
293T [246]
2 mM 15 h
replication block




2 mM 5 h dNTP depletion REF52 [74]
2 mM 3 h chromosomal aberrationsFANCD2 pathway involvement
lymphoblastoid
cell lines [247]
1 mM overnight replication block MCF7 [248]
0.5 mM 5 h–10 h replication block
U-2OS [249]
2 mM 2 h–24 h replication block
0.5 mM 90 min nucleotides depletion
stalled RF w/o DSBs formation MEF [250]
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Table 3. Cont.
Concentration Incubation Time Effect Cell Line Reference
0.1–0.5 mM 2 h–72 h γ-globin gene expression K562 [251]
0.1–0.5 mM 2 h–8 h replication stress PC3 [252]
0.2–0.4 mM 4 days
cell differentiation
ERK signalling pathway inhibition
p38 signal transduction activation
K562 [253]





0.15–0.2 mM 2 weeks irreversible senescence induction REF-52 [74]
0.2 mM 2 h–7 h replication stress MEF [255]
0.15 mM 2 h p53 activation REF52 [74]
50–200 µM 20 h HIF1 inductioneNOS induction
HUVEC [256]







5 µM–0.5 mM 48 h replication stress V79 hamstercells [217]
2 µM 12 h replication stress H1299 [258]
dNTP: deoxynucleotide triphosphate; DSBs: double-strand breaks; eNOS: endothelial nitric oxide synthase;
ERK: extracellular signal-regulated kinases; FANCD2: Fanconi anaemia complementation group D2; FANCJ: Fanconi
anaemia complementation group J; HIF: hypoxia induced factor 1.
2.3.3. Solubility
HU (MW 76.05 g/mol) is freely soluble in water at 100 mg/mL, soluble also in DMSO. The powder
is stable at 4 ◦C for 12 months. Solutions are stable for 1 month at−20 ◦C (after defrosting, equilibration
is recommended for 1 h at room temperature. It is recommended to prepare fresh solutions before use.
HU decomposes in the presence of moisture; therefore, it is recommended that it is stored in air-tight
containers in a dry atmosphere [259].
2.3.4. Medical Use
HU is a commonly used medicine first approved by the FDA for the treatment of neoplastic
disorders in the 1960s [260]. Common plasma levels of HU range 100–200 µM [261]. It is used
for the treatment of sickle cell disease, essential thrombocytosis [262], myeloproliferative disorders
and psoriasis [260] and is commonly indicated as a cytoreductive treatment in polycythemia
vera [263] and others. Synergistic effects have been reported when it is used in combination
with antiretroviral pills [264] and also in indicated cases with radiotherapy [265]. HU may be
used as an anti-retroviral agent, especially in HIV (human immunodeficiency virus) patients.
HU may cause myelofibrosis development with increased time of use and AML/MDS syndrome
(acute myeloid leukaemia/myelodysplastic syndrome) [266]. Adverse side-effects have been observed,
mainly myelosuppression [267]. A 17-year follow-up study of 299 patients treated with HU as a
long-term therapy showed no difference in the incidence of complications such as stroke, renal disease,
hepatic disease, malignancy or sepsis [268], suggesting that HU is well-tolerated. However, CNVs are
generated at therapeutic doses of HU, and data from reproductive studies and studies on subsequent
generations have so far been rather limited [236,268].
2.3.5. Summary
HU is used in vitro approx. in the range 2 mM–5 mM. The most commonly used concentrations are
around 2 mM. HU is used for cell cycle synchronization [269], replication fork stability studies [249,252],
studies of recovery mechanisms after the release of RS [242] and checkpoint responses [241].
Lower concentrations are used for RS induction [254], induction of senescence [74], apoptosis [257],
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and repair pathways induction [217]. HU reaches plasma concentrations around 0.1 mM; this should
be bear in mind when interpreting the data for clinical relevance [261]. The MRN (Mre11-Rad50-Nbs1)
complex members Mre11 (Meiotic recombination 11) and Nbs1 (Nijmegean breakage syndrome 1) are
required for efficient recovery of replication after treatment with replication stalling agents such as
hydroxyurea [12]. HU causes rapid generation of ssDNA as indicated by RPA loading 40 min after
treatment [270]. Subsequently, ATR-CHK1 signalling is activated, and HR repair pathway is induced.
Cells deficient in XRCC2 or other homologous recombination components exhibit hypersensitivity
to HU [271]. It was reported that for hamster V79 cells, low concentrations of HU (5–10 µM) mimics
the replication dynamics of untreated HR deficient cells [217]. Cellular senescence after long term
replication stress caused by HU is dependent on p53-p21 signalling pathway and independent
of p16 [74]. HU influences mutiple cellular pathways, e.g., JNK pathway, mitochondrial and
peroxisome biogenesis, expression of several heat shock response proteins, autophagy pathways
stimulation (beclin-1 expression), hemoglobin type F induction (in sickle cell disease, β-thalasemmia
patients), etc. [272]. There are several cell lines that response to HU treatment in a specific manner,
e.g., K562 cell line undergoes differentiation [253], T-cells activation is decreased [264], the morphology
of vascular endothelial cells is affected [273].
2.4. Camptothecin
Camptothecin (CPT) is a pentacyclic quinoline alkaloid first isolated from the Chinese tree
Camptotheca acuminata (Nyssaceae) by Wall et al. [274] (Figure 5). CPT has a unique intracellular target,
topoisomerase I (TopoI), a nuclear enzyme that reduces the torsional stress of supercoiled DNA [24].
This activity enables specific regions of DNA to become sufficiently exposed and relaxed to facilitate
essential cellular processes, such as DNA replication, recombination and transcription [275].
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Figure 5. Camptothecin structure.
2.4.1. Mechanism of DNA damage induction
TopoI binds covalently to double-stranded DNA through a reversible transesterification reaction,
generating a SSB [276], 3D structure can be foun here [277]. This so-called TopoI–DNA cleavage
complex (Top1cc) facilitates the relaxation of torsional strain in supercoiled DNA, either by allowing
passage of the intact single strand through the nick or by free rotation of the DNA around the uncleaved
strand [278]. CPT coval ntly and rev rsibly stabilises the normally transient DNA Top1cc by inhibiti g
religation of the scissile strand, thereby prolonging th half-life of Top1cc and increasing th number
of DNA SSBs [279,280]. Moreover, trapping of the enzyme on the DNA leads to rapid depletion of
the TopoI pool [281]. The effect of CPT is readily re sible after removal of the drug. How ver,
prolonge stabilisation of Top1cc can cause multiple problems. Firstly, failure to relieve superc iling
generated by such processes as transcripti n and replication can lead to RS by creating torsional strain
within the DNA [279,281,282]. Furthermore, the colli ion of the RF with th ternary drug-enzyme-DNA
omplex generates DSBs ith serious cellular consequences, including c ll death [283,284].
Because o going synthesis is important for CPT-induced cytotoxicity, CPT is onsidere an
S phase-specific drug. The repair of CPT-induced DSBs involves multiple DNA damage repair proteins.
Recent st dies have highlighted that functional cooperation between BRCA2, FANCD2, RAD18 an
RAD51 proteins are essential for repair of replication-associated DSBs through HR. Loss of any of
thes proteins causes disruption of HR r pair, chromosomal aber ti s and s sitization of cells to
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CPT [285]. A close link between CPT and HR has also been demonstrated in experiments measuring
sister chromatid exchange events (SCEs), which are common consequence of elevated HR repair
process and found to be induced by low doses of CPT [270]. CPT is applied in early S phase cells for
triggering G2 arrest accompanied by blockage of the p34cdc2/cyclin B complex, a consequence of either
DNA breakage, the arrest of the replication fork or both [286]. In addition, CPT driven TopoI–DNA
cleavable complex and associated strand breaks were shown to increase transcription of the c-Jun early
response gene, which occurs in association with internucleosomal DNA fragmentation, a characteristic
mark of apoptosis [287]. Noncytotoxic concentrations of CPT can induce the differentiation of human
leukaemia cells [288], and an antiangiogenic effect is suggested [289,290]. Interestingly, when used in
combined treatment with APH, CPT reduces the APH-induced RPA (an indicator of ssDNA) signal
and has a rescuing effect on CFS expression [291]. For references to particular studies using CPT,
refer to Table 4.
Table 4. Effects of various camptothecin treatments in vitro.
Concentration Incubation Time Observed Effect Cell Line Reference
20 µM 30 min DNA fragmentation in G1 and S phase cells Hela [292]
10 µM 24 h increase in cell sensitivity to TRAIL-mediatedapoptosis Hep3B [293]
10 µM 4 h formation of replication mediated DNA DSBs HT29 [294]
5 µM 60 min inhibition of RNA synthesis CSA [295]
1 µM 60 min inhibition of DNA synthesis CSB [296]





1 µM 60 min
formation of stabilised TopoI-cc complex
DSB formation phosphorylation of CHK1 (S317)
CHK2 (T68), RPA (S4/S8)
HCT116 [294]





200 nM–1 µM 50 min DSB formation CSB [298]
100 nM–10 nM 60 min DSB formation HCT116 [299]
25 nM 60 min
checkpoint activation (ATM-CHK2, ATR-CHK1)
replication fork stalling
replication fork reversal formation of specific
DNA structures
U-2O-S [300]
10 nM–100 nM 60 min inhibition of EIAV (equine infectious anemia virus)replication CF2Th [295]
10 nM–20 nM 60 min inhibition of HIV-1 replicationblock of viral protein expression H9 [281]
6 nM
6 h accumulation of cells in early S phase Normallymphocytes [296]
24 h apoptosis, DNA fragmentation MOLT-4
6.25 nM 48 h specific suppression of oral cancer cells growth KB oral cancercells [281]
2.5 nM 48 h increase in SCE upon depletion of Fbh1 helicase BJ [281]
ATM: Ataxia telangiectasia mutated; HIV: Human immunodeficiency virus; RPA: replication protein A; SCE: sister
chromatid exchange; TopoI-cc: Topoisomerase I cleavage complex; TRAIL: TNF alpha related apoptosis inducing
ligand, TNF: tumour necrosis factor.
2.4.2. Solubility
CPT (MW 348.35 g/mol) is soluble in DMSO (up to 10 mg/mL), methanol (40 mg/mL), 0.1 N
sodium hydroxide (50 mg/mL) or acetic acid, insoluble in water. At higher concentrations, heating is
required to dissolve the product completely (approx. 10 min at 95 ◦C), but some precipitation occurs
upon cooling to room temperature [301].
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2.4.3. Medical Use
CPT cannot be used in clinical practice because of its poor solubility in aqueous solutions,
instability and toxicity, but modifications at selected sites have improved the pharmacologic
and activity profile [283]. Currently, three water-soluble CPT-derivates, i.e., irinotecan (CPT-11),
topotecan (TPT) and belotecan (CKD-602), are available for cancer therapy. However, despite their
selectivity for TopoI and unique mechanism of action, they all have critical limitations. In particular,
they become inactivated against TopoI within minutes at physiological pH due to spontaneous
lactone E-ring opening [302] and diffuse rapidly from the TopoI–DNA cleavage complex due to
their noncovalent binding. To overcome these problems, five-membered E-ring CPT-keto non-lactone
analogues S38809 and S39625 have been synthesised and selected for advanced preclinical development
based on their promising activity in tumour models. Their chemical stability and ability to produce
high levels of persistent Top1cc makes them useful candidates for future treatment [303].
2.4.4. Summary
Camptothecin is used in concentration range 2.5 nM up to 20 µM. CPT is a potent DSBs inducer
in a wide concentration range, approx. 10 nM–10 µM. Upon higher concentration (20 µM–10 µM),
CPT was reported to be cytotoxic, increasing cell apoptosis via DNA fragmentation predominantly
in S phase cells with ongoing DNA synthesis [292,293]. The most frequently used concentration of
1 µM CPT was shown to block DNA synthesis and induce DSBs resulting from the collision of RF
due to prolonged stabilisation of TopoI DNA cleavage complex. The main implication of lower CPT
concentrations is the induction of replication fork slowing and reversal, as a rapid response to TopoI
inhibition is the increase in topological stress of DNA locally [300]. CPT activates predominantly
ATR-CHK1 and ATM-CHK2 signalling, and leading to G2 checkpoint arrest [300]. Even at low doses
of CPT HR repair pathway is triggered.
2.5. Etoposide
Etoposide (ETP) is a derivative of podophyllotoxin first synthetised in 1966 and approved
for treatment as an antineoplastic agent in 1983 [304]. ETP structure comprises of polycyclic A–D
rings, an E-ring and aglycone core (Figure 6). ETP compromises the proper function of the enzyme
topoisomerase II (TopoII), 3D structure can be found here [305]. TopoII performs cleavage of both
strands of a DNA duplex and enables passage of a second intact duplex through the transient break,
ATP is used to power the strand transition [306]. As a result, relaxation, unknotting and decatenation
of DNA are achieved enabling processes like replication and transcription [25].
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2.5.1. Mechanism of DNA Damage Induction
Two modes of action were suggested for ETP to interfere with TopoII [25]. As a poison, it stabilises
TopoII:DNA complexes, whereas as an inhibitor ETP interacts with the catalytic site of TopoII,
decreasing the number of active cleavage complexes [307]. ETP acts as a poison by stabilizing the
cleavage complex of TopoII via decoupling the key catalytic residues, thus preventing the religation of
cleaved DNA ends [308]. As a result, the number of TopoII-associated DNA breaks are increased [309].
ETP’s A, B and D-rings mediate the drug-enzyme interaction, whereas the aglycon core binds to
DNA [262,308]. E–ring substituents are important for ETP activity but do not contribute to ETP-enzyme
binding [310]. ETP is metabolised by cytochrome P3A4 (CYP3A4) to two metabolites, ETP-quinone
and ETP-catechol. Both active against the TopoII enzyme. ETP-quinone is approx. 100× more efficient
at inhibiting TopoII than ETP. ETP-quinone can block binding of the enzyme to DNA by stabilisation
of the N-terminal clamp [307]. In cases where the enzyme still binds to DNA, the metabolite can
stabilise the enzyme:DNA complex by inhibiting the religation step thus leading to higher levels of
DSBs [307]. The ETP-catechol metabolite works similarly to the parent compound but can also be
oxidised to the quinone [311]. ETP induces DSBs directly in all phases of the cell cycle, as observed by
γH2AX foci formation (a marker of DSBs) [312,313]. ETP does not require S-phase to induce damage,
but ongoing replication enhances its cytotoxic effect [314]. ETP causes disassembly of replication
factories (sites of ongoing replication), as measured by the distribution of proliferating cell nucelar
antigen protein (PCNA) [315]. Moreover, the cytotoxic effect of ETP is partially reduced by inhibitors
of DNA synthesis, such as APH and HU [316]. There are two isoforms of the TopoII enzyme in
mammals, called TopoIIα and TopoIIβ, sharing 68% homology [317]. TopoIIα activity is upregulated
during cell cycle progression, peaks in mitosis and is essential for proliferating cells [318]. TopoIIβ is
needed during transcription and DNA repair, and its levels are more stable during the cell cycle [319].
ETP is not selective between these two paralogs, and the inhibition of TopoIIβ is believed to be the
reason for ETP therapy-related secondary malignancies [320]. TopoIIα seems to be a better target for
therapy. Therefore, new compounds and analogues of ETP have been synthesised to be selective only
for TopoIIα [321].
2.5.2. Other Effects
A strong mutagenic effect has been measured for ETP in mammalian cells by several assays,
e.g., HPRT assay (hypoxanthine phosphoribosyl transferase), SCE and detection of mutations at the
locus of the adenosine kinase gene [322]. In prokaryotic organisms (E. coli, Salmonella typhimurium),
no significant genotoxic effect was observed [322]. For references to particular studies using ETP,
refer to Table 5.
Table 5. Effects of various etoposide treatments in vitro.
Concentration Incubation Time Effect Cell Line References
up to 450 µM 40 min
SSB and DSB formation, induction






1–100 µM 30 min








2–100 µM 6 h–48 h senescence, apoptosisinduction of p53 response
HepG2
U2OS [325]





50–100 µM 3–6 h/16 h apoptosis (activation of intrinsic(mitochondrial) pathway)
Hela
HCT116 [326]
50 µM 15 h apoptosis BJABHut78 [327]
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Table 5. Cont.
Concentration Incubation Time Effect Cell Line References
50 µM 48 h
growth arrest (accumulation of
cells at G2/M boundary)





25 µM 1 h







20 µM 16 h
increase in γH2AX levels
reduction of proliferation rate




















10 µM 1 h DNA damage induction A549 [334]
1–10 µM 48 h apoptosis HCC1937BT-549 [335]
8 µM 1 h induction of p53 response, SH-SY-5YSH-EP1 [336]
0.75–3 µM 72 h senescence, apoptosis A549 [337]
0.75 µM 24 h
cell cycle arrest in G2/M phase,
DNA damage induction,





DSBs: Double strand breaks; HIC1: Hypermethylated In Cancer 1; MDC1: Mediator of DNA Checkpoint 1; pATM:
phosphorylated Ataxia elangiectasia Mutated; pDNA-PKcs: phosphorylated DNA Protein Kinase catalytic subunit;
SSB: single-strand DNA break; TopoII: Topoisomerase II.
2.5.3. Solubility
ETP (MW 588.56 g/mol) is soluble in organic solvents (ethanol, methanol, DMSO), poorly soluble
in water. It is recommended that stock solutions in organic solvents be diluted so 0.1% organic solvent
is present in the final solution. The stability in aqueous solution is best at pH 4–5, but it can be
improved by adding polysorbate 80 (Tween80), polyethylene glycol 300, citric acid and alcohol. ETP is
unstable under oxidative conditions [338]. Under acidic conditions (pH < 4), the glycosidic linkage
and lactone ring are hydrolysed, whereas, under basic conditions (pH > 6), cis-lactone epimers are
formed [304]. Aqueous solutions are stable for several hours, depending on the concentration of the
solution but irrespective of the temperature. ETP is sensitive to UV irradiation, both in solution and as
a powder [338].
2.5.4. Medical Use
According to pharmacokinetic studies, plasma levels of ETP peak at concentrations of
20–70 µM [339]. ETP is approved for the treatment of refractory testicular tumors and small
cell lung cancer. Various chemical modifications with potential higher efficacy have also been
tested for clinical use, e.g., 4′-phosphorylation or 4′-propyl carboxy derivatives [340]. In the field
of so-called personalised medicine, combined subsequent treatment of ETP and cisPt has been
shown to be beneficial for patients suffering from ERCC1-incompetent lung adenocarcinoma [341].
ETP is reported to cause therapy-related leukaemias [320] and specific chromosomal translocations.
Chromosomal rearrangements at the 11q23 chromosome band were found in patients and seemed to be
related to the CYP3A4 metabolic conversion of ETP [342]. In mouse embryonic stem cells, an increase
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in fusion chimeric products was observed at a 1.5 kb “hot spot” between exons 9 and 11 (analogous
region to MLL (mixed lineage leukaemia) breakpoint cluster in human leukaemia) [343]. MLL gene
encodes lysine (K)-specific histone methyltransferase 2A therefore influencing histone methylation
and gene expression [344]. Leukaemogenic MLL translocations lead to expression of MLL fusion
proteins. Patients with such translocations exhibit poor prognosis [345]. MLL fusion proteins are
efficient in transforming the hematopoetic cells into leukaemia stem cells [346]. Many studies have
attempted to solve the adverse side effects of ETP treatment and understand the underlying molecular
mechanisms, e.g., multi-drug resistance [347], or unwanted toxicity [348]. The search for compounds
that may improve ETP treatment usually starts with cell-based experiments, e.g., protective compounds
shielding healthy cells [349], compounds selectively enhancing ETP toxicity [350] or targeted
delivery [351].
2.5.5. Summary
ETP is commonly used for the induction of apoptosis [352]. Indeed, several studies reported that
higher doses of the compound (25–100 µM) activate apoptosis, mostly in a manner dependent on
p53 [325–327,329]. Prolonged treatment at lower concentrations of ETP can also lead to induction of
the p53 pathway, cell cycle arrest, senescence and apoptosis [145,325,330,335,337]. ETP induces the
formation of irreversible DNA–TopoII cleavage complexes (TopoIIcc) and DNA damage regardless of
concentration or incubation time [323,324,329–332,334,353]. The initial displacement of TopoIIcc
requires the coordinated action of several processes, such as cleavage by the 5’-tyrosyl DNA
phosphodiesterase (TTRAP) and proteasome-dependent degradation of TopoII [354,355]. Furthermore,
the MRN complex, CtIP (RBBP8 protein) and BRCA1 play a critical role in the removal of such
DNA-protein adducts [356]. The remaining DNA lesions are often referred as DSBs, which are
accompanied by the activation of ATM-mediated signalling or repair pathways, usually quantified
by the formation of γH2AX [323,324,329–332]. However, several studies argue against the ability
of ETP to primarily induce DSBs, showing that majority of the DNA lesions formed upon ETP
treatment are SSBs [323,329]. Despite the discrepancy, pathways engaged in DSB repair are activated
after the exposure to the drug, and among them, NHEJ is seemingly predominant [329,356–358].
ETP used in relatively high concentration (20–25 µM) might lead to persistent or irreparable DSB
formation [329,331,332].
3. Conclusions
Replication stress is a significant contributor to genomic instability, a major factor for the
conservation of mutations [1], relevant promoter of tumourigenesis [8] and also one of the main features
of cancer cells [76]. Owing to its complexity, replication can be disturbed by multiple mechanisms.
In this review, we focused on several compounds known to be RS inducers and often used in cell-based
assays. Some of the compounds have been shown to be effective in cancer treatment. Importantly,
the chemicals have been primarily chosen to cover various mechanisms of action, resulting in different
treatment-induced phenotypes resembling those of RS in carcinogenesis. Induction of RS in vitro, e.g.,
by chemicals inducing DNA damage, is a crucial research tool. Precise knowledge about the mechanism
of DNA damage induction and cellular pathways involved in the RS response is particularly important
for the development of appropriate cellular assays for investigating carcinogenesis and cancer
treatment. The above-mentioned publications in separate compound-related tables were chosen
to help with the practical aspects of such assay design. Dose and time-dependent effects related to the
genetic backgrounds (i.e., dependent on the cell line used) and proper readout are important issues for
experiment design. Moreover, other practical information has been included so that readers can use
this review as a brief guide for choosing an appropriate model and dose scheme for cell-based studies.
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